F/TAF

DRUG11 trials

Sponsors

Gilead Sciences, Technical University of Munich

Conditions

Acquired Immune Deficiency Syndrome (AIDS)HIV InfectionsHIV-1HIV-1 InfectionHIV-1-infectionInsulin ResistancePre-Exposure Prophylaxis of HIV InfectionPre-Exposure Prophylaxis of HIV-1 Infection

Phase 1

Changes in Insulin Sensitivity in Healthy Volunteers Taking Tenofovir Alafenamide (TAF)-Containing Antiretroviral Medication

CompletedNCT03092206

Technical University of MunichInsulin Resistance

Start: 2017-04-18End: 2017-07-28Updated: 2017-08-21

Phase 2

Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV

Active, not recruitingNCT02016924

Gilead SciencesAcquired Immune Deficiency Syndrome (AIDS), HIV Infections

Start: 2014-01-16End: 2027-03-01Updated: 2026-03-20

Study To Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in Human Immunodeficiency Virus 1 (HIV-1) Infected Children and Adolescents Virologically Suppressed on a 2-Nucleoside/Nucleotide Reverse Transcriptase Inhibitor (2-NRTI)-Containing Regimen

CompletedNCT02285114

Gilead SciencesHIV-1

Start: 2015-01-20End: 2024-12-11Updated: 2025-06-27

Safety and Efficacy of Bictegravir + Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

CompletedNCT02397694

Gilead SciencesHIV-1 Infection

Start: 2015-03-23End: 2019-02-27Updated: 2020-04-07

Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With Other Antiretroviral Agents in People Living With HIV

CompletedNCT04143594

Gilead SciencesHIV-1-infection

Start: 2019-11-22End: 2023-09-19Updated: 2024-10-02

Phase 3

Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF

CompletedNCT02121795

Gilead SciencesHIV-1 Infection

Start: 2014-05-06End: 2019-03-01Updated: 2020-03-12

Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC

CompletedNCT02469246

Gilead SciencesHIV-1 Infection

Start: 2015-06-29End: 2019-03-13Updated: 2019-10-25

Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in Human Immunodeficiency Virus (HIV-1) Infected, Antiretroviral Treatment-Naive Adults

CompletedNCT02607956

Gilead SciencesHIV-1 Infection

Start: 2015-11-11End: 2021-07-05Updated: 2022-03-07

Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex With Men and Are At Risk of HIV-1 Infection

Active, not recruitingNCT02842086

Gilead SciencesPre-Exposure Prophylaxis of HIV-1 Infection

Start: 2016-09-02End: 2027-09-30Updated: 2025-11-13

Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Adults Who Are Virologically Suppressed

CompletedNCT03110380

Gilead SciencesHIV-1-infection

Start: 2017-06-12End: 2021-02-10Updated: 2022-01-11

Pre-Exposure Prophylaxis Study of Lenacapavir and Emtricitabine/Tenofovir Alafenamide in Adolescent Girls and Young Women at Risk of HIV Infection

Active, not recruitingNCT04994509

Gilead SciencesPre-Exposure Prophylaxis of HIV Infection

Start: 2021-08-30End: 2028-01-01Updated: 2026-03-30

Related Papers

P-299. No Clinically Significant Drug-Drug Interactions Between Lenacapavir and Hormonal Contraceptives in PURPOSE 1

Open Forum Infectious Diseases2026-01-01

Final efficacy and safety of twice-yearly subcutaneous lenacapavir in treatment-naïve people with HIV: randomized study.

2025-10-07

Longitudinal Evaluation of Bone Safety in Children and Adolescents With HIV-1 Starting Tenofovir Alafenamide-Containing Antiretroviral Therapy

Journal of the Pediatric Infectious Diseases Society2025-07-01

Long-term metabolic changes with bictegravir/emtricitabine/tenofovir alafenamide or dolutegravir-containing regimens for HIV.

2025-04-071 citations

Efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide in Black and Hispanic/Latine adults with <scp>HIV</scp>‐1 initiating first‐line therapy: 5‐year follow‐up from two phase III studies

HIV Medicine2025-03-21

Participant-reported Outcomes from the CAPELLA Clinical Trial of Lenacapavir-based Regimens in Heavily Treatment-experienced Adults with HIV

AIDS and Behavior2025-03-101 citations

HIV-1 infection kinetics, drug resistance, and long-term safety of pre-exposure prophylaxis with emtricitabine plus tenofovir alafenamide (DISCOVER): week 144 open-label extension of a randomised, controlled, phase 3 trial

2025-02-01

HIV Prevention Among Men Who Have Sex With Men: Tenofovir Alafenamide Combination Preexposure Prophylaxis Versus Placebo

UNC Libraries2025-01-30

P-512. Changes in Renal Function After Switching from Emtricitabine/Tenofovir Disoproxil Fumarate to Emtricitabine/Tenofovir Alafenamide Fumarate for HIV Pre-exposure Prophylaxis (PrEP): A Real-World Study

Open Forum Infectious Diseases2025-01-29

P-547. Efficacy and Safety of B/F/TAF in Treatment-Naïve People With HIV Aged ≥ 50 Years: 5-Year Follow-Up From Two Phase 3 Studies

Open Forum Infectious Diseases2025-01-29

P-550. Efficacy and Safety of B/F/TAF in Black Adults with HIV Who Are Treatment Naïve: 5-Year Follow-Up from Two Phase 3 Studies

Open Forum Infectious Diseases2025-01-29

Efficacy of bictegravir/emtricitabine/tenofovir alafenamide versus dolutegravir-based three-drug regimens in people with HIV with varying adherence to antiretroviral therapy

UNC Libraries2024-12-04

Efficacy of bictegravir/emtricitabine/tenofovir alafenamide versus dolutegravir-based three-drug regimens in people with HIV with varying adherence to antiretroviral therapy

Journal of Antimicrobial Chemotherapy2024-11-185 citations

Two 5-year studies of bictegravir/emtricitabine/tenofovir alafenamide in people with HIV: a plain-language summary

Future Microbiology2024-09-041 citations

Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women

New England Journal of Medicine2024-07-24338 citations

HIV-1 infection kinetics, drug resistance, and long-term safety of pre-exposure prophylaxis with emtricitabine plus tenofovir alafenamide (DISCOVER): week 144 open-label extension of a randomised, controlled, phase 3 trial.

2024-07-143 citations

Switch to bictegravir/emtricitabine/tenofovir alafenamide from dolutegravir-based therapy

AIDS2024-02-1311 citations

Gender Affirming Hormones Do Not Affect the Exposure and Efficacy of F/TDF or F/TAF for HIV Preexposure Prophylaxis: A Subgroup Analysis from the DISCOVER Trial.

2024-01-3111 citations

HIV Prevention Among Men Who Have Sex With Men: Tenofovir Alafenamide Combination Preexposure Prophylaxis Versus Placebo

The Journal of Infectious Diseases2023-11-161 citations

Bictegravir/emtricitabine/tenofovir alafenamide as initial treatment for HIV-1: five-year follow-up from two randomized trials.

2023-05-1162 citations

18 more papers not shown